SG11201607820QA - Serum albumin-binding fibronectin type iii domains - Google Patents
Serum albumin-binding fibronectin type iii domainsInfo
- Publication number
- SG11201607820QA SG11201607820QA SG11201607820QA SG11201607820QA SG11201607820QA SG 11201607820Q A SG11201607820Q A SG 11201607820QA SG 11201607820Q A SG11201607820Q A SG 11201607820QA SG 11201607820Q A SG11201607820Q A SG 11201607820QA SG 11201607820Q A SG11201607820Q A SG 11201607820QA
- Authority
- SG
- Singapore
- Prior art keywords
- serum albumin
- type iii
- fibronectin type
- iii domains
- binding fibronectin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461968181P | 2014-03-20 | 2014-03-20 | |
PCT/US2015/021535 WO2015143199A1 (en) | 2014-03-20 | 2015-03-19 | Serum albumin-binding fibronectin type iii domains |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201607820QA true SG11201607820QA (en) | 2016-10-28 |
Family
ID=52808189
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201607820QA SG11201607820QA (en) | 2014-03-20 | 2015-03-19 | Serum albumin-binding fibronectin type iii domains |
Country Status (14)
Country | Link |
---|---|
US (3) | US10442851B2 (en) |
EP (2) | EP3129401B1 (en) |
JP (2) | JP6591437B2 (en) |
KR (2) | KR20220162886A (en) |
CN (2) | CN113150117A (en) |
AU (1) | AU2015231170B2 (en) |
BR (1) | BR112016020175A2 (en) |
CA (1) | CA2943241C (en) |
EA (2) | EA202090216A3 (en) |
ES (2) | ES2913840T3 (en) |
IL (2) | IL275497B (en) |
MX (1) | MX2016011580A (en) |
SG (1) | SG11201607820QA (en) |
WO (1) | WO2015143199A1 (en) |
Families Citing this family (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201138808A (en) | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
CA2943241C (en) | 2014-03-20 | 2023-09-19 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type iii domains |
EP3224277B1 (en) | 2014-11-25 | 2020-08-26 | Bristol-Myers Squibb Company | Novel pd-l1 binding polypeptides for imaging |
EP3223866B1 (en) | 2014-11-25 | 2023-03-08 | Bristol-Myers Squibb Company | Methods and compositions for 18f-radiolabeling of the fibronectin type (iii) domain |
KR20180056701A (en) | 2015-09-23 | 2018-05-29 | 브리스톨-마이어스 스큅 컴퍼니 | Fast-off-rate serum albumin binding fibronectin type III domain |
BR112018010160A8 (en) * | 2015-11-19 | 2019-02-26 | Shire Human Genetic Therapies | recombinant human c1 esterase inhibitor and uses thereof |
CN107365387B (en) * | 2016-05-12 | 2022-03-15 | 阿思科力(苏州)生物科技有限公司 | Bispecific antigen binding construct, preparation method and application thereof |
US11339225B2 (en) | 2016-05-12 | 2022-05-24 | Asclepius (Suzhou) Technology Company Group, Co., Ltd. | Bispecific antigen-binding construct and preparation method and use thereof |
CN109562195A (en) | 2016-06-01 | 2019-04-02 | 百时美施贵宝公司 | PET imaging is carried out with PD-L1 combination polypeptide |
US10994033B2 (en) | 2016-06-01 | 2021-05-04 | Bristol-Myers Squibb Company | Imaging methods using 18F-radiolabeled biologics |
UA126021C2 (en) | 2016-06-03 | 2022-08-03 | Янссен Байотек, Інк. | Serum albumin-binding fibronectin type iii domains |
JP2019535267A (en) * | 2016-11-10 | 2019-12-12 | ケロス セラピューティクス インコーポレイテッドKeros Therapeutics,Inc. | GDNF fusion polypeptide and method of use thereof |
EP3554561B1 (en) | 2016-12-14 | 2023-06-28 | Janssen Biotech, Inc. | Cd137 binding fibronectin type iii domains |
CA3046963A1 (en) | 2016-12-14 | 2018-06-21 | Janssen Biotech, Inc. | Cd8a-binding fibronectin type iii domains |
US10597438B2 (en) | 2016-12-14 | 2020-03-24 | Janssen Biotech, Inc. | PD-L1 binding fibronectin type III domains |
GB201710973D0 (en) | 2017-07-07 | 2017-08-23 | Avacta Life Sciences Ltd | Scaffold proteins |
JP2021524756A (en) * | 2018-05-14 | 2021-09-16 | ウェアウルフ セラピューティクス, インコーポレイテッド | Activateable cytokine polypeptides and how to use them |
EP3793612A4 (en) * | 2018-05-16 | 2022-03-02 | LIB Therapeutics, LLC | Compositions comprising pcsk9-binding molecules and methods of use |
WO2021076574A2 (en) | 2019-10-14 | 2021-04-22 | Aro Biotherapeutics Company | Fn3 domain-sirna conjugates and uses thereof |
CN114786682A (en) | 2019-10-14 | 2022-07-22 | Aro生物疗法公司 | Fibronectin type III domain of CD71 |
WO2021074695A1 (en) | 2019-10-16 | 2021-04-22 | Avacta Life Sciences Limited | PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES. |
WO2021127353A1 (en) * | 2019-12-18 | 2021-06-24 | Aro Biotherapeutics Company | Serum albumin-binding fibronectin type iii domains and uses thereof |
GB202101299D0 (en) | 2020-06-09 | 2021-03-17 | Avacta Life Sciences Ltd | Diagnostic polypetides and methods |
CN112067806A (en) * | 2020-09-25 | 2020-12-11 | 徐州医科大学 | Application of Caspase-1 in preparation of medicine for improving CAR-T treatment effect |
KR102284800B1 (en) * | 2020-12-30 | 2021-08-03 | 주식회사 하플사이언스 | Medium composition for culturing animal cell for production of recombinant extracellular matrix proteins, and method using the same |
CN113307857B (en) * | 2021-01-14 | 2022-11-01 | 艾时斌 | Scaffold proteins derived from epidermal growth factor, lectin and Tat proteins |
EP4330383A1 (en) * | 2021-04-29 | 2024-03-06 | Novartis AG | Hypersialylating cells |
WO2022234003A1 (en) | 2021-05-07 | 2022-11-10 | Avacta Life Sciences Limited | Cd33 binding polypeptides with stefin a protein |
WO2023057567A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Pd-l1 binding affimers |
WO2023057946A1 (en) | 2021-10-07 | 2023-04-13 | Avacta Life Sciences Limited | Serum half-life extended pd-l1 binding polypeptides |
CN115386009B (en) * | 2022-04-26 | 2023-12-01 | 江苏靶标生物医药研究所有限公司 | Construction method and application of annexin V and angiogenesis inhibitor fusion protein |
WO2023218243A1 (en) | 2022-05-12 | 2023-11-16 | Avacta Life Sciences Limited | Lag-3/pd-l1 binding fusion proteins |
CN115724951B (en) * | 2022-11-15 | 2023-10-03 | 怡道生物科技(苏州)有限公司 | Antibodies or antigen binding fragments thereof that bind to HPV type 11 and uses thereof |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
USRE30985E (en) | 1978-01-01 | 1982-06-29 | Serum-free cell culture media | |
US4560655A (en) | 1982-12-16 | 1985-12-24 | Immunex Corporation | Serum-free cell culture medium and process for making same |
US4657866A (en) | 1982-12-21 | 1987-04-14 | Sudhir Kumar | Serum-free, synthetic, completely chemically defined tissue culture media |
US4767704A (en) | 1983-10-07 | 1988-08-30 | Columbia University In The City Of New York | Protein-free culture medium |
GB8516415D0 (en) | 1985-06-28 | 1985-07-31 | Celltech Ltd | Culture of animal cells |
US4927762A (en) | 1986-04-01 | 1990-05-22 | Cell Enterprises, Inc. | Cell culture medium with antioxidant |
US5514581A (en) | 1986-11-04 | 1996-05-07 | Protein Polymer Technologies, Inc. | Functional recombinantly prepared synthetic protein polymer |
US5641648A (en) | 1986-11-04 | 1997-06-24 | Protein Polymer Technologies, Inc. | Methods for preparing synthetic repetitive DNA |
US6018030A (en) | 1986-11-04 | 2000-01-25 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
US5770697A (en) | 1986-11-04 | 1998-06-23 | Protein Polymer Technologies, Inc. | Peptides comprising repetitive units of amino acids and DNA sequences encoding the same |
DE68925971T2 (en) | 1988-09-23 | 1996-09-05 | Cetus Oncology Corp | CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS |
FR2646437B1 (en) | 1989-04-28 | 1991-08-30 | Transgene Sa | NOVEL DNA SEQUENCES, THEIR APPLICATION AS A SEQUENCE ENCODING A SIGNAL PEPTIDE FOR THE SECRETION OF MATURE PROTEINS BY RECOMBINANT YEASTS, EXPRESSION CASSETTES, PROCESSED YEASTS AND PROCESS FOR PREPARING THE SAME |
AU8498091A (en) | 1990-08-02 | 1992-03-02 | Regents Of The University Of Colorado, The | Systematic polypeptide evolution by reverse translation |
US5122469A (en) | 1990-10-03 | 1992-06-16 | Genentech, Inc. | Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins |
US5773574A (en) | 1990-12-03 | 1998-06-30 | The Scripps Research Institute | Polypeptides for promoting cell attachment |
US5235041A (en) | 1990-12-28 | 1993-08-10 | Protein Polymer Technologies, Inc. | Purification of structurally ordered recombinant protein polymers |
US5792742A (en) | 1991-06-14 | 1998-08-11 | New York University | Fibrin-binding peptide fragments of fibronectin |
AU2313392A (en) | 1991-08-01 | 1993-03-02 | University Research Corporation | Systematic polypeptide evolution by reverse translation |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
WO1994017097A1 (en) | 1993-01-19 | 1994-08-04 | Regents Of The University Of Minnesota | Synthetic fibronectin fragments as inhibitors of retroviral infections |
AU8124694A (en) | 1993-10-29 | 1995-05-22 | Affymax Technologies N.V. | In vitro peptide and antibody display libraries |
US5559000A (en) | 1995-01-18 | 1996-09-24 | The Scripps Research Institute | Encoded reaction cassette |
DE19646372C1 (en) | 1995-11-11 | 1997-06-19 | Evotec Biosystems Gmbh | Conjugates of polypeptide and encoding nucleic acid |
GB9618960D0 (en) | 1996-09-11 | 1996-10-23 | Medical Science Sys Inc | Proteases |
US5922676A (en) | 1996-09-20 | 1999-07-13 | The Burnham Institute | Methods of inhibiting cancer by using superfibronectin |
EP1477561B1 (en) | 1996-10-17 | 2008-12-10 | Mitsubishi Chemical Corporation | Molecule assigning genotype to phenotype and use thereof |
US6261804B1 (en) | 1997-01-21 | 2001-07-17 | The General Hospital Corporation | Selection of proteins using RNA-protein fusions |
WO1998031700A1 (en) | 1997-01-21 | 1998-07-23 | The General Hospital Corporation | Selection of proteins using rna-protein fusions |
AU7266898A (en) | 1997-04-30 | 1998-11-24 | Enzon, Inc. | Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof |
US6673901B2 (en) | 1997-06-12 | 2004-01-06 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
US6159722A (en) | 1997-12-03 | 2000-12-12 | Boehringer Mannheim Gmbh | Chimeric serine proteases |
EP1068356B8 (en) | 1998-04-03 | 2007-01-03 | Adnexus Therapeutics, Inc. | Addressable protein arrays |
US7115396B2 (en) | 1998-12-10 | 2006-10-03 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
GB9827228D0 (en) | 1998-12-10 | 1999-02-03 | Univ Nottingham | Cancer detection method and reagents |
US6818418B1 (en) | 1998-12-10 | 2004-11-16 | Compound Therapeutics, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
CA2351346C (en) | 1998-12-10 | 2015-09-01 | Phylos, Inc. | Protein scaffolds for antibody mimics and other binding proteins |
WO2000064946A2 (en) | 1999-04-28 | 2000-11-02 | Board Of Regents, The University Of Texas System | Compositions and methods for cancer treatment by selectively inhibiting vegf |
ES2383332T3 (en) | 1999-07-27 | 2012-06-20 | Bristol-Myers Squibb Company | Peptide Acceptor Ligation Procedure |
EP1268544A2 (en) | 2000-03-31 | 2003-01-02 | Institut Pasteur | Peptides blocking vascular endothelial growth factor (vegf)-mediated angiogenesis, polynucleotides encoding said peptides and methods of use thereof |
JP2004515219A (en) | 2000-06-15 | 2004-05-27 | ボード・オブ・リージェンツ,ザ・ユニヴァーシティ・オヴ・テキサス・システム | Tunable catalytically active nucleic acids |
US8263741B2 (en) | 2000-07-11 | 2012-09-11 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
US7598352B2 (en) | 2000-11-17 | 2009-10-06 | University Of Rochester | Method of identifying polypeptide monobodies which bind to target proteins and use thereof |
WO2002081497A2 (en) | 2001-04-04 | 2002-10-17 | University Of Rochester | αξβ3 INTEGRIN-BINDING POLYPEPTIDE MONOBODIES AND THEIR USE |
CA2444854A1 (en) | 2001-04-26 | 2002-11-07 | Avidia Research Institute | Combinatorial libraries of monomer domains |
WO2003022858A2 (en) | 2001-09-11 | 2003-03-20 | Nascacell Gmbh | Method for screening for inhibitors of protein/protein interaction and corresponding ribozymes |
US20080193445A1 (en) | 2002-01-18 | 2008-08-14 | Liliane Goetsch | Novel anti-IGF-IR antibodies and uses thereof |
WO2003104418A2 (en) | 2002-06-06 | 2003-12-18 | Research Corporation Technologies, Inc. | Reconstituted polypeptides |
US9321832B2 (en) | 2002-06-28 | 2016-04-26 | Domantis Limited | Ligand |
US20080220049A1 (en) | 2003-12-05 | 2008-09-11 | Adnexus, A Bristol-Myers Squibb R&D Company | Compositions and methods for intraocular delivery of fibronectin scaffold domain proteins |
KR20060129246A (en) | 2003-12-05 | 2006-12-15 | 컴파운드 쎄라퓨틱스, 인크. | Inhibitors of type 2 vascular endothelial growth factor receptors |
JP2008512352A (en) | 2004-07-17 | 2008-04-24 | イムクローン システムズ インコーポレイティド | Novel tetravalent bispecific antibody |
US7597884B2 (en) | 2004-08-09 | 2009-10-06 | Alios Biopharma, Inc. | Hyperglycosylated polypeptide variants and methods of use |
FR2888850B1 (en) | 2005-07-22 | 2013-01-11 | Pf Medicament | NOVEL ANTI-IGF-IR ANTIBODIES AND THEIR APPLICATIONS |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
AP2008004418A0 (en) | 2005-10-07 | 2008-04-30 | Univ California | Nucleic acids encoding modified cytochrome p450 enzyme and methods of use thereof |
KR20160137665A (en) | 2005-11-23 | 2016-11-30 | 악셀레론 파마 인코포레이티드 | Activin-actrπa antagonists and uses for promoting bone growth |
KR20080097188A (en) | 2006-02-24 | 2008-11-04 | 키에시 파르마슈티시 엣스. 피. 에이. | Anti-amyloid immunogenic compositions, methods and use |
JP2009534331A (en) | 2006-04-21 | 2009-09-24 | トランジェーヌ、ソシエテ、アノニム | Papillomavirus vaccine mainly composed of HPV-18 |
WO2008031098A1 (en) | 2006-09-09 | 2008-03-13 | The University Of Chicago | Binary amino acid libraries for fibronectin type iii polypeptide monobodies |
US20110143953A1 (en) | 2006-10-16 | 2011-06-16 | Arizona Board Of Regents, A Body Corporate Of The State Of Arizona | Synthetic Antibodies |
AU2007325838B2 (en) | 2006-11-22 | 2013-09-19 | Bristol-Myers Squibb Company | Targeted therapeutics based on engineered proteins for tyrosine kinases receptors, including IGF-IR |
US20100144599A1 (en) | 2007-02-02 | 2010-06-10 | Bristol-Myers Squibb Company | Vegf pathway blockade |
WO2008108986A2 (en) | 2007-03-02 | 2008-09-12 | Amgen Inc. | Methods and compositions for treating tumor diseases |
JP5781762B2 (en) | 2007-08-10 | 2015-09-24 | プロテリックス、インク | Universal type III fibronectin binding domain library |
US8680019B2 (en) | 2007-08-10 | 2014-03-25 | Protelica, Inc. | Universal fibronectin Type III binding-domain libraries |
US8470966B2 (en) | 2007-08-10 | 2013-06-25 | Protelica, Inc. | Universal fibronectin type III binding-domain libraries |
WO2009025806A2 (en) | 2007-08-20 | 2009-02-26 | Adnexus, A Bristol-Myers Squibb R & D Company | Use of vegfr-2 inhibitors for treating metastatic cancer |
RU2010121967A (en) | 2007-10-31 | 2011-12-10 | Медиммун, Ллк (Us) | PROTEIN FRAME FRAME STRUCTURES |
WO2009073115A1 (en) | 2007-11-28 | 2009-06-11 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with mtor inhibitors |
CA2709994A1 (en) | 2007-12-19 | 2009-07-09 | Centocor Ortho Biotech Inc. | Non-antibody scaffold protein fusions phage display via fusion to pix of m13 phage |
CA2710835A1 (en) * | 2007-12-27 | 2009-07-09 | Novartis Ag | Improved fibronectin-based binding molecules and their use |
MX2010008874A (en) | 2008-02-14 | 2010-09-22 | Bristol Myers Squibb Co | Targeted therapeutics based on engineered proteins that bind egfr. |
EP2274331B1 (en) | 2008-05-02 | 2013-11-06 | Novartis AG | Improved fibronectin-based binding molecules and uses thereof |
AR071874A1 (en) | 2008-05-22 | 2010-07-21 | Bristol Myers Squibb Co | ARMAZON DOMAIN PROTEINS BASED ON MULTIVALENT FIBRONECTINE |
US8415291B2 (en) | 2008-10-31 | 2013-04-09 | Centocor Ortho Biotech Inc. | Anti-TNF alpha fibronectin type III domain based scaffold compositions, methods and uses |
CA2741834C (en) | 2008-10-31 | 2022-04-05 | Centocor Ortho Biotech Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
TWI496582B (en) | 2008-11-24 | 2015-08-21 | 必治妥美雅史谷比公司 | Bispecific egfr/igfir binding molecules |
EA201100943A1 (en) | 2008-12-16 | 2012-05-30 | Новартис Аг | YEAST DISPLAY SYSTEMS |
WO2010093771A1 (en) | 2009-02-11 | 2010-08-19 | Bristol-Myers Squibb Company | Combination vegfr2 therapy with temozolomide |
EP2396011B1 (en) | 2009-02-12 | 2016-04-13 | Janssen Biotech, Inc. | Fibronectin type iii domain based scaffold compositions, methods and uses |
US8067201B2 (en) | 2009-04-17 | 2011-11-29 | Bristol-Myers Squibb Company | Methods for protein refolding |
US20120270797A1 (en) | 2009-08-13 | 2012-10-25 | Massachusetts Institute Of Technology | Engineered proteins including mutant fibronectin domains |
US9139825B2 (en) | 2009-10-30 | 2015-09-22 | Novartis Ag | Universal fibronectin type III bottom-side binding domain libraries |
WO2011051466A1 (en) | 2009-11-02 | 2011-05-05 | Novartis Ag | Anti-idiotypic fibronectin-based binding molecules and uses thereof |
US20110123545A1 (en) | 2009-11-24 | 2011-05-26 | Bristol-Myers Squibb Company | Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases |
WO2011092233A1 (en) | 2010-01-29 | 2011-08-04 | Novartis Ag | Yeast mating to produce high-affinity combinations of fibronectin-based binders |
WO2011100700A2 (en) | 2010-02-12 | 2011-08-18 | University Of Rochester | Antigenic mimics of discontinuous epitopes of pathogen recognized by broadly neutralizing antibodies |
AU2011218243A1 (en) * | 2010-02-18 | 2012-10-04 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind IL-23 |
US8420098B2 (en) | 2010-04-13 | 2013-04-16 | Bristol-Myers Squibb Company | Fibronectin based scaffold domain proteins that bind to PCSK9 |
MX341119B (en) | 2010-04-13 | 2016-08-09 | Medimmune Llc | Trail r2-specific multimeric scaffolds. |
AU2011245225B2 (en) | 2010-04-30 | 2015-09-17 | Janssen Biotech, Inc. | Stabilized fibronectin domain compositions, methods and uses |
TW201138808A (en) * | 2010-05-03 | 2011-11-16 | Bristol Myers Squibb Co | Serum albumin binding molecules |
ES2573108T3 (en) | 2010-05-26 | 2016-06-06 | Bristol-Myers Squibb Company | Fibronectin-based framework proteins that have improved stability |
AU2011283646B2 (en) * | 2010-07-30 | 2015-07-09 | Novartis Ag | Fibronectin cradle molecules and libraries thereof |
JP2014504587A (en) | 2010-12-22 | 2014-02-24 | ブリストル−マイヤーズ スクイブ カンパニー | Fibronectin-based scaffold domain protein that binds to IL-23 |
HUE033008T2 (en) | 2011-04-13 | 2017-11-28 | Bristol Myers Squibb Co | Fc fusion proteins comprising novel linkers or arrangements |
EP2709669A1 (en) | 2011-05-17 | 2014-03-26 | Bristol-Myers Squibb Company | Methods for maintaining pegylation of polypeptides |
EP2710382B1 (en) | 2011-05-17 | 2017-10-18 | Bristol-Myers Squibb Company | Improved methods for the selection of binding proteins |
KR102035713B1 (en) | 2011-09-27 | 2019-10-24 | 얀센 바이오테크 인코포레이티드 | Fibronectin type iii repeat based protein scaffolds with alternative binding surfaces |
US9522951B2 (en) | 2011-10-31 | 2016-12-20 | Bristol-Myers Squibb Company | Fibronectin binding domains with reduced immunogenicity |
MY172863A (en) | 2012-09-13 | 2019-12-13 | Bristol Myers Squibb Co | Fibronectin based scaffold domain proteins that bind to myostatin |
WO2014165093A2 (en) * | 2013-03-13 | 2014-10-09 | Bristol-Myers Squibb Company | Fibronectin based scaffold domains linked to serum albumin or a moiety binding thereto |
EP3647322B1 (en) | 2014-03-20 | 2021-10-20 | Bristol-Myers Squibb Company | Stabilized fibronectin based scaffold molecules |
CA2943241C (en) | 2014-03-20 | 2023-09-19 | Bristol-Myers Squibb Company | Serum albumin-binding fibronectin type iii domains |
KR20180056701A (en) * | 2015-09-23 | 2018-05-29 | 브리스톨-마이어스 스큅 컴퍼니 | Fast-off-rate serum albumin binding fibronectin type III domain |
-
2015
- 2015-03-19 CA CA2943241A patent/CA2943241C/en active Active
- 2015-03-19 BR BR112016020175A patent/BR112016020175A2/en active Search and Examination
- 2015-03-19 SG SG11201607820QA patent/SG11201607820QA/en unknown
- 2015-03-19 EP EP15714135.9A patent/EP3129401B1/en active Active
- 2015-03-19 EP EP19170042.6A patent/EP3572424B1/en active Active
- 2015-03-19 KR KR1020227041649A patent/KR20220162886A/en not_active Application Discontinuation
- 2015-03-19 AU AU2015231170A patent/AU2015231170B2/en active Active
- 2015-03-19 KR KR1020167028794A patent/KR102472862B1/en active IP Right Grant
- 2015-03-19 CN CN202110321688.3A patent/CN113150117A/en active Pending
- 2015-03-19 ES ES19170042T patent/ES2913840T3/en active Active
- 2015-03-19 WO PCT/US2015/021535 patent/WO2015143199A1/en active Application Filing
- 2015-03-19 MX MX2016011580A patent/MX2016011580A/en unknown
- 2015-03-19 CN CN201580014557.3A patent/CN106170494B/en active Active
- 2015-03-19 EA EA202090216A patent/EA202090216A3/en unknown
- 2015-03-19 ES ES15714135T patent/ES2736127T3/en active Active
- 2015-03-19 EA EA201691669A patent/EA034886B1/en not_active IP Right Cessation
- 2015-03-19 US US15/127,166 patent/US10442851B2/en active Active
- 2015-03-19 IL IL275497A patent/IL275497B/en unknown
- 2015-03-19 JP JP2016558031A patent/JP6591437B2/en active Active
-
2016
- 2016-09-14 IL IL247825A patent/IL247825B/en active IP Right Grant
-
2019
- 2019-08-23 US US16/549,462 patent/US11203630B2/en active Active
- 2019-09-18 JP JP2019168989A patent/JP7132898B2/en active Active
-
2021
- 2021-11-16 US US17/527,238 patent/US20220204589A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL275497A (en) | Serum albumin-binding fibronectin type iii domains | |
IL282960B (en) | Serum albumin-binding fibronectin type iii domains | |
HUE053370T2 (en) | Method for mode switching | |
IL252696B (en) | Protein manufacture | |
SG11201704010UA (en) | Fibroin-derived protein composition | |
IL267140B (en) | Cd8a-binding fibronectin type iii domains | |
GB201600378D0 (en) | Not title | |
IL246603B (en) | Novel anti-netrin-1 antibody | |
PL3099791T3 (en) | Protein | |
GB201415344D0 (en) | Protein | |
LT3628731T (en) | Novel anti-presepsin antibody | |
PL3099793T3 (en) | Protein | |
GB201417447D0 (en) | Improved immunoassay for pyrrolidinophenones | |
GB201412797D0 (en) | Proteins | |
GB201412646D0 (en) | Proteins | |
GB201412648D0 (en) | Proteins | |
GB201412649D0 (en) | Proteins | |
GB201406894D0 (en) | Proteins | |
GB201405955D0 (en) | Proteins | |
GB201405952D0 (en) | Proteins | |
GB201403915D0 (en) | Proteins | |
GB201403912D0 (en) | Proteins | |
GB201403913D0 (en) | Proteins | |
GB201403914D0 (en) | Proteins | |
GB201414371D0 (en) | Protein modification |